for Multiple Myeloma
Vaccination with Dendritic Cell/Myeloma Fusion Post-Transplant for Multiple Myeloma
The BMT CTN 1401 study was designed as a Phase II, multicenter trial of vaccination with Dendritic Cell (DC)/myeloma fusions with granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF following autologous transplant as part of upfront treatment of multiple myeloma. In this whitepaper, we compare the proportion of patients alive and in complete response at one-year post-transplant between patients receiving DC/myeloma vaccine/GM-CSF with lenalidomide maintenance therapy to those receiving lenalidomide maintenance therapy with or without GM-CSF.
- Outline of challenges and how they were overcome
- Trial outcome
- Highlights and achievements
- Success factors
- Key Data
Find out how Emmes is making advances by downloading the whitepaper today!